

Table 2.

Solvent system	Partition coefficients (K)						
	Pure compounds designed below			Components in adrenal vein blood			
	DC	P	Δ^4 -A	x	x-Ac	y	z
<i>n</i> -Hexane / 50 % ethanol + 50 % H ₂ O	0.09	0.9	0.08	10	6.7	2.70	8.1
<i>n</i> -Hexane / 75 % ethanol + 25 % H ₂ O				0.67			
<i>n</i> -Hexane / 90 % ethanol + 10 % H ₂ O				0.41			

DC: Δ^4 -Pregnene-21-ol-3,20-dione (Cortexone)

P: Δ^4 -Pregnene-3,20-dione (Progesterone)

Δ^4 -A: Δ^4 -Androstene-3,17-dione

x-Ac: The acetate of the unknown component "x"

not due to the sulfuric acid alone which in itself gave rise to a double peak at 320 and 345 μ .

1. Carstensen, H. *Acta Chem. Scand.* **9** (1955) 1026.
2. Pincus, G. and Pearlman, W. H. *Endocrinology* **29** (1941) 413.
3. Mader, W. J. and Buck, R. R. *Anal. Chem.* **24** (1952) 666.
4. Wilson, H. and Fairbanks, R. *Arch. Biochem. and Biophys.* **53** (1954) 71.
5. Wilson, H. *Arch. Biochem. and Biophys.* **52** (1954) 217.
6. Norymberski, J. K. *Nature* **170** (1952) 1074.
7. Kober, S. *Biochem. Z.* **239** (1931) 209.

Received September 6, 1955.

Semimicro Synthesis of Dihydrouracil and Uracil Labeled in Position 4, 5 or 6 with Carbon ¹⁴C

PER FRITZSON*

Norsk Hydro's Institute for Cancer Research,
The Norwegian Radium Hospital,
Oslo, Norway

Recent evidence indicates the dihydropyrimidines as intermediates in the catabolism of the pyrimidine bases. Lie-

* Fellow of the "Norwegian Cancer Society", Oslo, Norway.

berman *et al.*^{1,2} have reported the isolation of an enzyme system from an anaerobic soil bacterium which reduced orotic acid to dihydroorotic acid. Di Carlo *et al.*³ suggested dihydrouracil as an intermediate in uracil catabolism from studies on the assimilation of nitrogen by *Torula utilis*. The breakdown of dihydrouracil to β -alanine in rat liver slices is shown by Fink *et al.*⁴, and Funk *et al.*⁵ reported the isolation of dihydrouracil from beef spleen.

For further investigation of the metabolism of uracil and dihydrouracil and their biological relation, a semimicro synthesis of the two pyrimidines labeled in position 4, 5 or 6 has been worked out, using potassium cyanide-¹⁴C or chloroacetic acid labeled with ¹⁴C in the 2 or 1-position, respectively, as starting materials.

126 mg of potassium cyanide containing 2 mC of ¹⁴C were treated with 244 mg of the potassium salt of chloroacetic acid, and the resultant potassium cyanoacetate was catalytically hydrogenated under a pressure of 2 atm. at 18° for 11 hours to β -alanine^{6,7}. After two crystallizations from alcohol-water the crude β -alanine was reacted with 160 mg of potassium cyanate at 25°, forming the potassium salt of β -ureidopropionic acid^{8,9}. Treatment of the crude product with hydrochloric acid and subsequent heating of the dry substance to 170° yielded 119 mg (56 % based on chloroacetic acid) of dihydrouracil-4-¹⁴C crystallized from water. On recrystallization from water, adding charcoal, the product melted at 274–275° (reported¹⁰ m. p. 275–276°). The theoretical specific activity was 9.1 μ C per mg.

40 mg of the dihydrouracil were brominated according to the method of Gabriel¹¹. Subsequent heating of the crude product to 200° yielded 34.6 mg (88 % based on dihydrouracil) of uracil-4-¹⁴C crystallized from water. On recrystallization from water, adding charcoal, the product melted at 335° as reported¹⁰ for uracil. The theoretical specific activity was 9.1 μ C per mg.

Attempts to prepare uracil by oxidation of dihydrouracil by alloxan according to Johnson¹² were unsuccessful.

Preparation of β -ureidopropionic acid labeled in the 1, 2 or 3-position is accomplished readily in aqueous solution according to Batt *et al.*³ by decomposition in alkali of dihydrouracil labeled in position 6, 5 or 4 respectively.

The author wishes to thank Miss Jorunn Lassen for technical assistance in the synthesis of dihydrouracil.

1. Lieberman, I. and Kornberg, A. *Federation Proc.* **12** (1953) 239.
2. Lieberman, I. and Kornberg, A. *Biochim. et Biophys. Acta* **12** (1953) 223.
3. Di Carlo, F. J., Schultz, A. S. and Kent, A. M. *J. Biol. Chem.* **199** (1952) 333.
4. Fink, R. M., Fink, K. and Henderson, R. B. *J. Biol. Chem.* **201** (1953) 349.
5. Funk, C., Merritt, A. J. and Ehrlich, A. *Arch. Biochem. and Biophys.* **35** (1952) 468.
6. Fritzsøn, P. and Eldjarn, L. *Scand. J. Clin. Lab. Invest.* **4** (1952) 375.
7. Ruggli, P. and Businger, A. U.S.P. 2, 367, 436 (1945).
8. Lengfeld, F. and Stieglitz, J. *Am. Chem. J.* **15** (1893) 516.
9. Gabriel, S. *Ber.* **38** (1905) 635.
10. Fischer, E. and Roeder, G. *Ber.* **34** (1901) 3759.
11. Gabriel, S. *Ber.* **38** (1905) 637, 1690.
12. Johnson, T. B. *J. Am. Chem. Soc.* **63** (1941) 263.
13. Batt, R. D., Martin, J. K., Ploeser, J. McT. and Murray, J. *J. Am. Chem. Soc.* **76** (1954) 3663.

Received September 1, 1955.